Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-11-01
|
| Series: | Frontiers in Public Health |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpubh.2022.1059495/full |
| _version_ | 1811232984800428032 |
|---|---|
| author | Jia Liu Jia Liu Lidan Cao Lidan Cao Jing Wu Jing Wu |
| author_facet | Jia Liu Jia Liu Lidan Cao Lidan Cao Jing Wu Jing Wu |
| author_sort | Jia Liu |
| collection | DOAJ |
| first_indexed | 2024-04-12T11:12:31Z |
| format | Article |
| id | doaj.art-a702b69d5f8648a48228d0b9c39c637c |
| institution | Directory Open Access Journal |
| issn | 2296-2565 |
| language | English |
| last_indexed | 2024-04-12T11:12:31Z |
| publishDate | 2022-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Public Health |
| spelling | doaj.art-a702b69d5f8648a48228d0b9c39c637c2022-12-22T03:35:34ZengFrontiers Media S.A.Frontiers in Public Health2296-25652022-11-011010.3389/fpubh.2022.10594951059495Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in ChinaJia Liu0Jia Liu1Lidan Cao2Lidan Cao3Jing Wu4Jing Wu5School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, ChinaCenter for Social Science Survey and Data, Tianjin University, Tianjin, ChinaSchool of Pharmaceutical Science and Technology, Tianjin University, Tianjin, ChinaCenter for Social Science Survey and Data, Tianjin University, Tianjin, ChinaSchool of Pharmaceutical Science and Technology, Tianjin University, Tianjin, ChinaCenter for Social Science Survey and Data, Tianjin University, Tianjin, Chinahttps://www.frontiersin.org/articles/10.3389/fpubh.2022.1059495/fullcost-utilitylurasidoneolanzapinerisperidoneschizophrenia |
| spellingShingle | Jia Liu Jia Liu Lidan Cao Lidan Cao Jing Wu Jing Wu Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China Frontiers in Public Health cost-utility lurasidone olanzapine risperidone schizophrenia |
| title | Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China |
| title_full | Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China |
| title_fullStr | Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China |
| title_full_unstemmed | Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China |
| title_short | Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China |
| title_sort | corrigendum cost utility analysis of lurasidone for the first line treatment of schizophrenia in china |
| topic | cost-utility lurasidone olanzapine risperidone schizophrenia |
| url | https://www.frontiersin.org/articles/10.3389/fpubh.2022.1059495/full |
| work_keys_str_mv | AT jialiu corrigendumcostutilityanalysisoflurasidoneforthefirstlinetreatmentofschizophreniainchina AT jialiu corrigendumcostutilityanalysisoflurasidoneforthefirstlinetreatmentofschizophreniainchina AT lidancao corrigendumcostutilityanalysisoflurasidoneforthefirstlinetreatmentofschizophreniainchina AT lidancao corrigendumcostutilityanalysisoflurasidoneforthefirstlinetreatmentofschizophreniainchina AT jingwu corrigendumcostutilityanalysisoflurasidoneforthefirstlinetreatmentofschizophreniainchina AT jingwu corrigendumcostutilityanalysisoflurasidoneforthefirstlinetreatmentofschizophreniainchina |